Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103551 | 1.00 | LMNA (0.40) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL6772912 | 0.84 | LMNA (0.38) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL6772922 | 0.84 | LMNA (0.38) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL5764664 | 0.82 | LMNA (0.38) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL5766908 | 0.82 | LMNA (0.38) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL4375219 | 0.82 | HTR1A (0.47) | LMNASMN1; SMN2ALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL4372252 | 0.82 | HTR1A (0.47) | LMNASMN1; SMN2ALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL4363802 | 0.81 | LMNA (0.39) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL4906739 | 0.81 | LMNA (0.37) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL6628114 | 0.81 | LMNA (0.37) | LMNACA2SMN1; SMN2ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7479500-B2 | Antidepressant piperidine derivatives of heterocyclefused benzodioxans | WYETH (US) | 2009-01-20 | — | — | US | disclosed |
| US-7419986-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7381723-B2 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2008-06-03 | — | — | US | disclosed |
| US-7335666-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1537122-B9 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1537122-B1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-7153849-B2 | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| US-6617334-B2 | Inhibiting the reuptake of serotonin in a subject suffering from postraumatic stress, ADD, premenstrual dysphoria, obesity, eating disorder, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-6613913-B2 | Intermediate for antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta [a]naphthalene | WYETH | 2003-09-02 | — | — | US | disclosed |
| US-20030134871-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | WYETH | 2003-07-17 | — | — | US | disclosed |
| US-6525075-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020183336-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002090362-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002088145-A1 | AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183354-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | OPRD1, HTR1A, HTR1D | LMNA 3605/4885CA2 4615/4885SMN1; SMN2 1769/4885 |
| US-20030134871-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE | OPRD1, HTR1A, HTR1D | LMNA 3605/4885CA2 4615/4885SMN1; SMN2 1769/4885 |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | LMNA 2334/4885CA2 4770/4885SMN1; SMN2 2518/4885 |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | LMNA 2278/4885CA2 490/4885SMN1; SMN2 4616/4885 |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | HTR1A, HTR5A, HTR1D | LMNA 3767/4885CA2 4510/4885SMN1; SMN2 964/4885 |
| US-20020183336-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | HTR1A, HTR5A, HTR1D | LMNA 2591/4885CA2 4702/4885SMN1; SMN2 526/4885 |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, CYP19A1, HTR5A | LMNA 1663/4885CA2 4830/4885SMN1; SMN2 2730/4885 |
| US-20090042895-A1 | Antidepressant Piperidine Derivatives of Heterocycle-Fused Benzodioxans | HTR5A, OPRD1, CRH | LMNA 1546/4885CA2 4833/4885SMN1; SMN2 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.